Tarsus Pharmaceuticals price target raised to $105 from $95 at Oppenheimer

Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $105 from $95 and keeps an Outperform rating on the shares following quarterly results. Importantly, management provided first-time FY26 net product sales guidance of $670M-$700M for XDEMVY, representing a year-over-year increase of $230M driven by new-patient demand, broad payer coverage, and direct-to-consumer effectiveness, putting XDEMVY on track to achieve $2B-plus in U.S. peak sales.